Ventavis® is an established inhaled prostacyclin analogue for the treatment of primary pulmonary hypertensionAcquisition reinforces Essential ...

Medication nonadherence in pulmonary arterial hypertension (PAH) significantly increases the risk of mortality and poor clinical outcomes.

Pulmonary hypertension (PH) is a complex and often misunderstood condition characterized by high blood pressure in the arteries of the lungs. Unlike systemic hypertension – the "regular" high blood ...

Panelists discuss how pulmonary arterial hypertension diagnosis requires comprehensive evaluation including right heart catheterization to confirm hemodynamic criteria, with normal mean PA pressure ...

BACKGROUND: BCR-ABL tyrosine kinase inhibitors (TKIs) have been increasingly linked to pulmonary arterial hypertension (PAH) since 2009, although supporting evidence is limited. Our objective was to ...

Can a one-minute sit-to-stand test predict long-term outcomes in pulmonary hypertension? New data suggest it can. Read more.

Pulmonary hypertension is traditionally defined as a mean pulmonary artery pressure of ≥25 mmHg when a patient is at rest, though a mean pressure of >20 mm Hg is considered to be abnormal and may ...

Researchers have uncovered the pivotal role of a previously overlooked protein in the development of the serious illness.

A rare association exists between pulmonary hypertension (PH) and hematologic malignancies, particularly AML evolving from MPN. The case study involves a 32-year-old woman with JAK2 mutation-positive ...

As the world marks Rare Disease Month, health experts are urging greater awareness of conditions that often go unnoticed ...

We read with great interest the research letter by Niemiec et al 1 on the use of sacubitril / valsartan in patients with pulmonary hypertension (PH) due to heart failure with preserved ejection ...